Mirtazapine


Tetracyclic atypical antidepressant (NaSSA)

A noradrenergic and specific serotonergic antidepressant; a tetracyclic with strong H1 antihistamine activity producing pronounced sedation and appetite stimulation.

Abstract

Mirtazapine ((R/S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; CAS 85650-52-8; molecular formula C17H19N3; molecular weight 265.36) is a tetracyclic NaSSA (noradrenergic and specific serotonergic antidepressant) developed at Organon and approved by the FDA in 1996 under the trade name Remeron. Mechanism distinguishes the compound from the SSRI/SNRI class: rather than inhibiting transporters, mirtazapine antagonizes presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors, increasing both norepinephrine and serotonin release. Concurrent 5-HT2A and 5-HT2C antagonism redirects the released serotonin preferentially to 5-HT1A receptors. Strong H1 histamine antagonism (Ki approximately 0.14 nM, comparable to first-generation antihistamines) produces sedation and weight gain, often dose-limiting at higher doses. The compound has minimal activity at muscarinic, dopaminergic, or transporter sites. Plasma half-life is 20 to 40 hours; metabolism is via CYP2D6, CYP3A4, and CYP1A2. Approved for major depressive disorder; widely used off-label for insomnia and as an appetite stimulant. Used as a reference compound in alpha-2 adrenergic and 5-HT2 receptor pharmacology.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph